03
Oct
2024
14:00
BST
09:00
EDT
Webinar
Characterisation of Zanubrutinib Safety and Tolerability Profile and Comparison With Ibrutinib Safety Profile in Patients With B-Cell Malignancies: Post-hoc Analysis of a Large Clinical Trial Safety Database
-
Views:
949
-
Likes:
4
Overview
Join Dr Rohan Bhandari (Washington University, St Louis, US), Dr Jose Alvarez-Cardona (New York University School of Medicine, US) and Dr Dan Lenihan (Saint Francis Healthcare System, US) for this month's Journal Club where faculty will tackle critical research in the developing field of cardio-oncology.
Learn about the safety and tolerability profiles of Zanubrutinib and Ibrutinib in patients with B-cell malignancies. Our expert panel will compare outcomes from a large safety database, helping you understand critical differences and potential impacts on patient care.
The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.
This webinar is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.
Support Statement
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BeiGene, BMS/Pfizer Alliance, Eli Lilly and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.
Faculty:
Rohan Bhandari
Jose Alvarez-Cardona
Dan Lenihan
This webinar is supported by
Faculty Biographies
Rohan Bhandari
Dr Rohan Bhandari is a 3rd year fellow-in-training in General Cardiology and Cardio-Oncology and Cardiac Amyloidosis at Washington University in St Louis, US. Additional academic and clinical interests in advanced cardiovascular imaging, aortopathy and vascular medicine.
Jose Alvarez-Cardona
Dr Jose Alvarez-Cardona is a Cardiologist and Assistant Professor at New York University School of Medicine, New York, US.
He received his medical degree from University of Puerto Rico School of Medicine. He specialises in cardiomyopathy and heart failure. His specialities include cardiac amyloidosis, cardiomyopathy and heart failure, congestive heart failure, heart transplant and left ventricular assist devices.
Dan Lenihan
Dr Dan Lenihan is a cardio-oncologist specialising in cardiology, heart disease and advanced heart failure, at Saint Francis Healthcare System, Cape Girardeau, US.
He is a co-Founder and Board Member of the International Cardio-Oncology Society (ICOS), which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
He is actively involved in patient care as the Director of the Cardio-Oncology Programme, Cardiac Rehabilitation, and the Heart Failure clinic at Saint Francis Healthcare System.